Solifenacin demonstrates high absolute bioavailability in healthy men

被引：19
作者：
Kuipers M.E. [1 ]
Krauwinkel W.J.J. [1 ]
Mulder H. [1 ]
Visser N. [1 ]
机构：
[1] Yamanouchi Europe BV, Leiderdorp
来源：
Drugs in R & D | 2004年 / 5卷 / 2期
关键词：
Overactive Bladder; Oxybutynin; Tolterodine; Absolute Bioavailability; Solifenacin;
D O I：
10.2165/00126839-200405020-00002
中图分类号：
学科分类号：
摘要：
Objective: Solifenacin succinate (YM905; Vesicare®) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10mg, which is twice the suggested starting dose. Study design: Single-centre, open-label, randomised, two-period, crossover, single-dose study. Methods: Solifenacin was administered orally as a 10mg dose and intravenously as a 5mg dose. Oral and intravenous (IV) doses were divided by a washout period of ≥14 days. Study participants: The study group consisted of 12 healthy young men, aged 20-45 years, nine of whom completed the study. Results: The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence. Conclusions: Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents. © 2004 Adis Data Information BV. All rights reserved.
引用
收藏
页码：73 / 81
页数：8
相关论文
共 17 条
  • [1] Abrams P., Cardozo L., Fall M., Et al., The standardization of terminology of lower urinary tract function: Report from the standardization sub-committee of the International Continence Society, Neurourol. Urodyn., 21, pp. 167-178, (2002)
  • [2] Wyndaele J.J., The overactive bladder, BJU Int., 88, pp. 135-140, (2001)
  • [3] Stewart W., Herzog R., Wein A., Et al., The prevalence and impact of overactive bladder in the US: Results from the NOBLE program, Neurourol. Urodyn., 20, pp. 406-408, (2001)
  • [4] Milsom I., Stewart W., Thuroff J., The prevalence of overactive bladder, Am. J. Manag. Care, 6, (2000)
  • [5] Abrams P., Kelleher C.J., Kerr L., Et al., Overactive bladder significantly affects quality of life, Am. J. Manag. Care, 6, SUPPL. 11, (2000)
  • [6] Cardozo L., Kuzmin I., Lisec M.L., Et al., YM905 in symptomatic overactive bladder: Results of a Phase 3A randomised, placebo-controlled trial, J. Urol., 169, SUPPL. 4, (2003)
  • [7] Chapple C.R., Arano P., Bosch J.L.H.R., Et al., YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase II, dose-finding study, Neurourol. Urodyn., 21, pp. 381-382, (2002)
  • [8] Smith N., Grimes I., Ridge S., Et al., YM905 is effective and safe as treatment of overactive bladder in women and men: Results from phase II study, (2002)
  • [9] Ikeda K., Kobayashi S., Suzuki M., Et al., M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland, Naunyn Schmiedebergs Arch. Pharmacol., 366, pp. 97-103, (2002)
  • [10] Smulders R.A., Krauwinkel W., Abila B., Et al., 10- and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic: Pharmacokinetics, pharmacodynamic, and safety in healthy, elderly men and women, (2002)
12